WHO Issues Medical Alert on Falsified Semaglutide Medicines
The World Health Organization (WHO) has released a critical medical product alert regarding falsified semaglutide medicines. These medications, commonly used to treat type 2 diabetes and obesity, have been identified as falsified in multiple countries, raising significant health concerns.
Detection of Falsified Semaglutide Batches
Three falsified batches of semaglutide medicines, specifically the brand Ozempic, were detected in Brazil and the United Kingdom in October 2023, and in the United States in December 2023. Since 2022, the WHO Global Surveillance and Monitoring System (GSMS) has reported a surge in falsified semaglutide products across various regions. This alert marks the first official notice from WHO after confirming several reports.
Dr. Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, emphasized, “WHO advises healthcare professionals, regulatory authorities, and the public to be aware of these falsified batches of medicines. We call on stakeholders to cease any use of suspicious medicines and report to relevant authorities.”
Also, read: Complete Details on Diabetes Screening Test: What 7 Blood Tests Does It Cover?
Supply Shortages and Increased Falsification
Semaglutides, including the falsified brand, are prescribed to individuals with type 2 diabetes to help lower blood sugar levels and reduce cardiovascular risks. These medicines are available as weekly injections or daily tablets and have also been increasingly prescribed for weight loss due to their appetite-suppressing effects.
The WHO has noted a growing demand for semaglutide medicines alongside increasing reports of falsification. These counterfeit products pose significant health risks. If the medicines lack the required active components, patients may face unmanaged blood glucose levels or other complications. Some falsified products may contain undeclared active ingredients, such as insulin, leading to unpredictable health outcomes.
Cost Barriers and Public Health Concerns
Semaglutides are currently not part of WHO-recommended diabetes treatments due to their high cost. This expense renders them impractical for broad public health initiatives, which aim to provide accessible medications to large populations, especially in resource-limited settings. More affordable alternatives are available that offer similar benefits for managing blood sugar and cardiovascular risks.
WHO’s Response and Future Guidelines
The WHO is developing rapid advice guidelines on the potential use of GLP-1 RAs, including semaglutides, for treating obesity in adults. GLP-1 RAs, or glucagon-like peptide-1 receptor agonists, are a class of medicines used to lower blood sugar and support weight loss in diabetes treatment.
Also, watch web stories: What Does It Feel Like to Go Through Menopause?
Protecting Against Falsified Medicines
To safeguard against falsified medicines, patients using semaglutides should:
- Purchase medications only with prescriptions from licensed physicians.
- Avoid buying medicines from unverified sources, including online vendors.
- Always check packaging and expiry dates.
- Follow storage instructions, particularly keeping injectable semaglutides refrigerated.
By remaining vigilant and informed, patients can protect themselves from the dangers of falsified medicines and ensure they receive safe and effective treatment. (Source) (Source)
